Antiestrogen therapy is active in selected ovarian cancer cases: the use of letrozole in estrogen receptor–positive patients

…, ARW Williams, AA Nafussi, T Rye, R Rye… - Clinical Cancer …, 2007 - AACR
Purpose: To evaluate the efficacy of the aromatase inhibitor letrozole in preselected estrogen
receptor (ER)–positive relapsed epithelial ovarian cancer patients and to identify markers …

Carcinosarcoma of the ovary: 19 years of prospective data from a single center

E Brown, M Stewart, T Rye, A Al‐Nafussi… - … Journal of the …, 2004 - Wiley Online Library
BACKGROUND A review of clinicopathologic features and outcome in women with carcinosarcoma
of the ovary (also known as malignant mixed mesodermal tumor [MMMT]) compared …

Endometrioid epithelial ovarian cancer: 20 years of prospectively collected data from a single center

DJ Storey, R Rush, M Stewart, T Rye, A Al‐Nafussi… - Cancer, 2008 - Wiley Online Library
BACKGROUND. Clinicopathological features and outcome of women with endometrioid
and serous ovarian adenocarcinoma were compared. METHODS. Between 1984 and 2004, …

[HTML][HTML] Molecular stratification of endometrioid ovarian carcinoma predicts clinical outcome

…, B Stanley, M Churchman, AM Meynert, T Rye… - Nature …, 2020 - nature.com
Endometrioid ovarian carcinoma (EnOC) demonstrates substantial clinical and molecular
heterogeneity. Here, we report whole exome sequencing of 112 EnOC cases following …

[HTML][HTML] Expression of glycolytic enzymes in ovarian cancers and evaluation of the glycolytic pathway as a strategy for ovarian cancer treatment

…, A Turnbull, CO Michie, ARW Williams, T Rye… - BMC cancer, 2018 - Springer
Background Novel therapeutic approaches are required to treat ovarian cancer and dependency
on glycolysis may provide new targets for treatment. This study sought to investigate …

[PDF][PDF] Increased incidence of visceral metastases in Scottish patients with BRCA1/2-defective ovarian cancer: an extension of the ovarian BRCAness phenotype

…, N Reed, RL Hayward, P Mitchell, T Rye… - Journal of Clinical …, 2010 - researchgate.net
… Hayward, Paul Mitchell, Tzyvia Rye, Jan HM Schellens, Jan Lubinski, James Carmichael,
Stan B. Kaye, Melanie Mackean, and Michelle Ferguson … Hayward, Michelle Ferguson …

[HTML][HTML] Ovarian carcinosarcoma is a distinct form of ovarian cancer with poorer survival compared to tubo-ovarian high-grade serous carcinoma

RL Hollis, I Croy, M Churchman, C Bartos, T Rye… - British journal of …, 2022 - nature.com
Background Ovarian carcinosarcoma (OCS) is an uncommon, biphasic and highly aggressive
ovarian cancer type, which has received relatively little research attention. Methods We …

Structural Variants at the BRCA1/2 Loci are a Common Source of Homologous Repair Deficiency in High-grade Serous Ovarian Carcinoma

…, GR Grimes, RL Hollis, CS Herrington, T Rye… - Clinical Cancer …, 2021 - AACR
Purpose: The abundance and effects of structural variation at BRCA1/2 in tumors are not well
understood. In particular, the impact of these events on homologous recombination repair …

Patterns of clinicopathological features and outcome in epithelial ovarian cancer patients: 35 years of prospectively collected data

A Irodi, T Rye, K Herbert, M Churchman… - … Journal of Obstetrics …, 2020 - Wiley Online Library
Objective Investigate the clinical landscape of ovarian carcinoma (OC) over time. Design
Register‐based prospectively collected data. Setting South East Scotland. Sample A total of …

High EMSY expression defines a BRCA‐like subgroup of high‐grade serous ovarian carcinoma with prolonged survival and hypersensitivity to platinum

RL Hollis, M Churchman, CO Michie, T Rye, L Knight… - Cancer, 2019 - Wiley Online Library
Background Approximately half of high‐grade serous ovarian carcinomas (HGSOCs) demonstrate
homologous recombination repair (HR) pathway defects, resulting in a distinct clinical …